Clinical trials: IV Injection
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
- Trial name
- NCT07189195
- Testing
- TR-002
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of California, Davis
Healthy Volunteers
Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects
This Phase I is designed to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of M201-A administered by multiple continuous intravenous injection in Healthy Japanese subjects.
- Trial name
- NCT04464681
- Testing
- M201-A Injection
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kitasato University
Hypogonadotropic Hypogonadism
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
- Trial name
- NCT00328926
- Testing
- Luveris® 75 IU, Luveris® 25 IU, Recombinant human follicle stimulating hormone (r-hFSH)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- EMD Serono
Relapsing-remitting Multiple Sclerosis
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
- Trial name
- NCT00078338
- Testing
- Rebif®, Copaxone®
- Where
- 80 sites in United States, Argentina and 10 more
- Volunteers
- 764 people
- Sponsor
- EMD Serono
Nausea With Vomiting Chemotherapy-Induced
Buccal Film Versus IV Injection Palonosetron for Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting
Phase 2 study to compare efficacy, safety and PK of palonosetron, a long acting 5-HT3 receptor antagonist, by buccal film delivery compared to iv injection for chemotherapy induced nausea or vomiting (CINV).
- Trial name
- NCT04592198
- Testing
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Two Forms of Pentamidine in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS
To compare parenteral versus inhaled pentamidine in patients with documented Pneumocystis carinii pneumonia (PCP) with AIDS.
- Trial name
- NCT00002292
- Testing
- Pentamidine isethionate
- Where
- United States
- Sponsor
- LyphoMed
Cerebrovascular Accident, Muscle Spasticity
Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm
The main purpose of this study is to assess the effect on Quality of Life of two cycles of Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on spasticity and function will also be measured.
- Trial name
- NCT00216411
- Testing
- Botulinum toxin type A
- Where
- 6 sites in Australia
- Volunteers
- 96 people
- Sponsor
- Ipsen
Healthy
A Study of IBI311 in Healthy Volunteers
It is designed for Multi-center, double-masked, randomized, placebo- control study with dose escalation phase I trial to evaluate the safety, tolerability, PK and immunogenicity profiles of a single intravenous injection of…
- Trial name
- NCT05480579
- Testing
- IBI311
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Amyotrophic Lateral Sclerosis
Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS
ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and…
- Trial name
- NCT01759797
- Testing
- intra venous injection of stem cell
- Where
- Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
PONV
Phase IIIb Study of APD421 in Combination as PONV Prophylaxis
A comparison of the efficacy of APD421 and placebo when combined with a standard anti-emetic in the prevention of PONV in patients at high risk of Post-operative Nausea and Vomiting (PONV).
- Trial name
- NCT02337062
- Testing
- APD421
- Where
- 25 sites in United States, France and 1 more
- Volunteers
- 1,147 people
- Sponsor
- Acacia Pharma Ltd
Cytomegalovirus Infection, Adenovirus Infection
Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus
With this study, we want to see if we can use a kind of white blood cell called T cells to prevent or treat AdV and CMV infection. We will grow these T cells from the cord blood before the patients transplant.
- Trial name
- ACT-CAT (NCT00880789)
- Testing
- CMV/AdV specific T cells
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Baylor College of Medicine
Acute Pain
Clinical Study Comparing the Efficacy of Transbuccal Paracetamol 125 mg Versus Paracetamol Injection 1g in Slow Infusion IV in Patients With Acute Pain
This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to…
- Trial name
- PARAJUG (NCT01586143)
- Testing
- paracetamol
- Where
- France
- Volunteers
- 43 people
- Sponsor
- University Hospital, Clermont-Ferrand
Metastatic Cancer, Cancer
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as…
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Trial name
- NCT01957735
- Testing
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- BPGbio
Pain
J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion
To measure and compare pain associated with venipuncture and peripheral intravenous catheter insertion among pediatric emergency department patients randomized to treatment with one of three different pain-reduction strategies…
- Trial name
- NCT00924963
- Testing
- J-Tip jet injector, Jet injection saline, lidocaine cream
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cardiovascular Diseases, Atherosclerosis
Clinical Transfer of a Vulnerable Atherosclerotic Plaque Tracer : 99mTc-cAbVCAM1-5 (ATHENA)
Clinical Transfer of a Tracer of the Vulnerable Atheroma Plate: 99mTc-cAbVCAM1-5. (ATHENA). This is a phase I/IIa, prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.
- Trial name
- ATHENA (NCT04483167)
- Testing
- 99mTccAbVCAM1-5 injection
- Where
- France
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Colorectal Cancer Stage IV
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sintilimab (R\&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity.
- Trial name
- NCT05171660
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Rendu Osler Disease
Calcium-phosphate Complications Induced by IV Iron Supplementation in Patients With Rendu-Osler Disease
Hypophosphatemia induced by treatments with injectable iron is a frequent side effect already reported during marketing. Situations of osteomalacia secondary to these hypophosphatemias are rarer and reported in the form of case…
- Trial name
- OS-LERETRO (NCT05544669)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Strasbourg, France
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Lung Cancer Metastatic
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer
The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.
- Trial name
- NCT04311762
- Testing
- cisplatin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Vermont
Crigler-Najjar Syndrome Type I
Gene Therapy for Crigler Najjar Syndrome Type I (AlphaCN)
This is a Phase 1/2, multinational, open-label, study to evaluate the safety and efficacy of an intravenous infusion of GT-UGT1A1-AAV8-02 in patients with Crigler-Najjar type 1 aged ≤10 years and requiring phototherapy.
- Trial name
- NCT06641154
- Testing
- GT-UGT1A1-AAV8-02
- Where
- 2 sites in Russia
- Volunteers
- 5 people
- Sponsor
- Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare